Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-19

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

NCT03485092

Heart Failure Diabetes Mellitus

COMPLETED PHASE4

Empagliflozin Reversal of Arterial StiffnEss in Aging

NCT06506422

Aging Arterial Stiffness

RECRUITING PHASE2/PHASE3

SGLT2 Inhibition in Diabetes and Heart Failure

NCT02862067

Diabetes Mellitus, Type 2 Heart Failure, Systolic

COMPLETED

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

NCT06507657

Hypertension Cardiovascular Diseases

RECRUITING EARLY_PHASE1

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

NCT04535960

Type 2 Diabetes Mellitus

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension is the leading risk factor of heart failure with preserved heart failure. The overall control rate is about 16% in China. Given the large amounts of hypertensive patients at pre-heart failure (stage B), it's critical to explore the effect of additional cardioprotective medication in addition to well-controlled blood pressure. Sodium-glucose cotransporter-2 inhibitors (engagliflozin) have been shown to improve cardiac function or prognosis in patients with diabetes or heart failure. However, whether it has a cardioprotective effect on hypertensive patients with pre-heart failure and without diabetes remains unknown. We will conduct a multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes. We will enroll 120 eligible patients randomized to receive a placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. The secondary endpoints include echocardiography or magnetic resonance imaging to measure structural and functional parameters, blood pressure, glucose, and blood biomarkers of inflammation and fibrosis. We sought to comprehensively evaluate the effect of empagliflozin on the structure and function and explore the underlying mechanisms to provide insights and evidence for the prevention of heart failure in hypertensive patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Heart Failure Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Empagliflozin

Group Type EXPERIMENTAL

Empagliflozin 10 MG

Intervention Type DRUG

Each participant in the empagliflozin treatment group takes a daily dose of 10mg.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Each participant in the placebo group takes matching placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Empagliflozin 10 MG

Each participant in the empagliflozin treatment group takes a daily dose of 10mg.

Intervention Type DRUG

Placebo

Each participant in the placebo group takes matching placebo.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jardiance®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Meeting all the following criteria:

1. Aged 40 and above; less than 75 years.
2. Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (\<140/90 mmHg).
3. The left atrial volume index measured by transthoracic echocardiography exceeds 34 mL/m², or the ratio of the average E/e' \>9 and left atrial volume index \>= 29 mL/m² measured by transthoracic echocardiography.
4. Signing an informed consent form.

Exclusion Criteria

1. History of diabetes.
2. History of heart failure.
3. History of coronary artery disease.
4. Left ventricular systolic dysfunction, defined as LVEF \< 50%.
5. Systolic blood pressure \< 100 mmHg.
6. A history of arrhythmias such as atrial fibrillation, atrial flutter, frequent atrial premature contractions, and frequent ventricular premature contractions may impact the structural and functional aspects of the heart.
7. Moderate and above valvular heart disease.
8. Severe obstructive disease of the left ventricular outflow tract, including aortic valve stenosis.
9. Visited within the past 1 month due to Genitourinary tract infection.
10. Chronic kidney disease or estimated Glomerular Filtration Rate (eGFR) \< 45 ml/min/1.73m².
11. Alanine aminotransferase or aspartate aminotransferase levels \> 3 times the upper limit of normal.
12. Contraindications to taking SGLT2 inhibitors.
13. Currently taking SGLT2 inhibitors, SGLT-1/2 inhibitors, or other antihyperglycemic medications (including metformin, glucagon-like peptide-1 receptor agonists, etc.).
14. Pregnancy or planning pregnant, or currently breastfeeding.
15. Malignant tumors or other severe illnesses with a life expectancy of less than 3 years.
16. History of alcohol abuse or substance abuse within the past year.
17. Mental disorders or communication barriers, cognitive impairments, or other severe illnesses that may affect participation in the study.
18. Participation in or currently participating in other clinical trials within the last 3 months.
19. Known poor compliance with study follow-up or study drug.
20. Any condition or contraindication that makes a person intolerant to magnetic resonance imaging (MRI) or contraindicates MRI examination, such as the presence of implanted intracranial aneurysm clips, cardiac pacemakers or defibrillators, insulin pumps, etc.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No